Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Employees

334

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/26/09	5.350 $	-3.25%	13,22,932
06/26/06	5.530 $	-2.30%	17,26,764
05/26/05	5.660 $	+1.25%	52,07,983
04/26/04	5.590 $	+35.35%	1,05,39,296
03/26/03	4.130 $	-3.73%	13,35,505

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.350USD

Average target price

14.67USD

Spread / Average Target

+174.14%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:00 10/03/2026 am IST			5-day change	1st Jan Change
5.350 ^USD	-3.25%		+24.71%	-19.55%

04/03	Top Premarket Gainers	MT
04/03	Evolus, Inc., Q4 2025 Earnings Call, Mar 03, 2026

Capitalization	35Cr 30Cr 27Cr 26Cr 47Cr 3.21TCr 49Cr 320.11Cr 128.37Cr 1.53TCr 130.66Cr 127.85Cr 5.5TCr	P/E ratio 2026 *	-10x	P/E ratio 2027 *	-34.1x
Enterprise value	47Cr 40Cr 37Cr 35Cr 64Cr 4.32TCr 67Cr 431.39Cr 172.99Cr 2.07TCr 176.08Cr 172.3Cr 7.42TCr	EV / Sales 2026 *	1.42x	EV / Sales 2027 *	1.23x
Free-Float	79.24%	Yield 2026 *	-	Yield 2027 *	-

04/03	Top Premarket Gainers	MT
04/03	Evolus, Inc., Q4 2025 Earnings Call, Mar 03, 2026
04/03	Evolus Inc - enters loan and security agreement with Eclipse Business Capital on March 3, 2026 - SEC filing	RE
04/03	Evolus Posts Q4 Breakeven Results, Revenue Rises; Shares Gain After Hours	MT
04/03	Evolus, Inc. Enters into a Loan and Security Agreement with Eclipse Business Capital LLC	CI
04/03	Evolus, Inc. Provides Earnings Guidance for 2026	CI
04/03	Evolus, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
04/02	AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs	RE
09/01	Evolus, Inc. Reaffirms Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Provides Preliminary Unaudited Earnings Guidance for the Year 2025 and Maintains Unaudited Earnings Guidance for the Year 2026 and Provides Earnings Guidance for the Year 2028	CI
09/01	Evolus outlook FY sales USD 327-337 million	RE
15/11	Evolus reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
13/11	AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly similar Functional Analysis Data	CI
12/11	Tandem Diabetes Care, Inc. Appoints Sandra Beaver to Board of Directors, Effective November 7, 2025	CI

12/11	Tandem Diabetes Care, Inc. Appoints Sandra Beaver to Board of Directors, Effective November 7, 2025	CI
17/25/17	BTIG Initiates Evolus at Buy With $21 Price Target	MT
08/24/08	Mizuho Securities Adjusts Evolus Price Target to $23 From $20, Maintains Buy Rating	MT
29/24/29	Barclays Upgrades Evolus to Overweight From Equalweight, Raises Price Target to $16 From $10	MT
03/23/03	HC Wainwright Adjusts Price Target on Evolus to $27 From $16, Maintains Buy Rating	MT

Evolus, Inc. Share Price

Equities

EOLS

US30052C1071

Pharmaceuticals

Valuation: Evolus, Inc.

Chart: Evolus, Inc.

Latest news: Evolus, Inc.

Last Transcript: Evolus, Inc.

Analysts' recommendations: Evolus, Inc.

Press Releases: Evolus, Inc.

News in other languages: Evolus, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Evolus, Inc.

ETFs: Evolus, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

04/03	Evolus : Investor Presentation	PU
04/03	Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026	BU
25/02	Evolus to Participate in The Leerink Partners Global Healthcare Conference	BU
17/02	Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026	BU
14/02	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU

25/19/25	USA-Les valeurs à suivre à Wall Street (actualisé)
05/19/05	Dow Jones Industrial Average : Wall Street termine en hausse, soutenue par les techs
05/19/05	Point marchés-Wall Street termine en hausse, soutenue par les techs (actualisé)
04/19/04	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
04/19/04	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	-3.25%
1 week	+24.71%
Current month	+24.42%
1 month	+26.18%
3 months	-23.35%
6 months	-27.60%
Current year	-19.55%

1 week	5.06	6.25
1 month	4.09	6.25
Current year	4.09	6.77
1 year	4.09	13.66
3 years	4.09	17.82
5 years	4.09	17.82
10 years	2.85	39.5

Manager	Title	Age	Since
David Moatazedi CEO	Chief Executive Officer	48	06/05/2018
Tatjana Mitchell DFI	Director of Finance/CFO	48	08/09/2025
Rui Avelar CTO	Chief Tech/Sci/R&D Officer	64	01/01/2014

Director	Title	Age	Since
Vikram Malik CHM	Chairman	63	01/01/2018
David Gill BRD	Director/Board Member	71	12/02/2018
David Moatazedi BRD	Director/Board Member	48	06/05/2018

Name		Varia. Jan 1.	Weight	AuM
VANGUARD US TOTAL MARKET SHARES INDEX ETF		-7.99%	0%	293,477 M€
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD		+3.88%	0%	7 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EVOLUS, INC.	-3.25%	+24.71%	-60.60%	-37.65%	35Cr
ELI LILLY AND COMPANY	+1.82%	-0.94%	+15.96%	+218.25%	90TCr
JOHNSON & JOHNSON	+0.91%	-2.40%	+45.53%	+60.40%	58TCr
ABBVIE INC.	-1.16%	-2.91%	+6.14%	+54.36%	40TCr
ROCHE HOLDING AG	+2.17%	-4.53%	+10.38%	+28.69%	34TCr
NOVARTIS AG	+1.57%	-2.39%	+21.70%	+65.34%	31TCr
ASTRAZENECA PLC	+2.27%	-1.07%	+24.74%	+38.08%	30TCr
MERCK & CO., INC.	+1.14%	-3.54%	+23.73%	+8.84%	29TCr
AMGEN INC.	+2.01%	-2.26%	+16.04%	+66.96%	20TCr
GILEAD SCIENCES, INC.	+1.88%	-2.27%	+24.89%	+85.73%	18TCr
Average	+0.76%	-0.69%	+12.85%	+58.90%	35.11TCr
Weighted average by Cap.	+0.91%	-3.10%	+21.57%	+93.09%

	2026 *	2027 *
Net sales	33Cr 28Cr 26Cr 25Cr 45Cr 3.04TCr 47Cr 303.76Cr 121.81Cr 1.46TCr 123.99Cr 121.33Cr 5.22TCr	39Cr 33Cr 30Cr 29Cr 53Cr 3.58TCr 55Cr 357.11Cr 143.21Cr 1.71TCr 145.77Cr 142.63Cr 6.14TCr
Net income	-3.56Cr -3.07Cr -2.77Cr -2.66Cr -4.83Cr -327.85Cr -5.05Cr -33Cr -13Cr -156.83Cr -13Cr -13Cr -562.8Cr	-1.07Cr -92.59L -83.62L -80.13L -1.46Cr -99Cr -1.52Cr -9.87Cr -3.96Cr -47Cr -4.03Cr -3.94Cr -169.76Cr
Net Debt	12Cr 10Cr 9.43Cr 9.03Cr 16Cr 1.11TCr 17Cr 111.28Cr 45Cr 533.24Cr 45Cr 44Cr 1.91TCr	13Cr 11Cr 9.97Cr 9.56Cr 17Cr 1.18TCr 18Cr 117.72Cr 47Cr 564.09Cr 48Cr 47Cr 2.02TCr